-Alimentiv and Satisfai Health announce the commercial availability of an innovative AI-based scoring tool for the evaluation of ulcerative colitis in phase I to IV clinical trials
LONDON, ON and VANCOUVER, BC, Oct. 10, 2023/PRNewswire/ — Alimentiv, a global contract research organization (CRO) providing clinical trials, central image management, precision medicine and real-world evidence services to the pharmaceutical and biotechnology industries, and Satisfai Health, a Vancouver-based software company focused on the application of artificial intelligence for the assessment of gastrointestinal diseases, announce the commercial availability of Satisfai Health’s Certai product as an automated, data-powered solution. AI for secondary analysis of endoscopic video in phase I to IV IBD clinical trials. Certai will be available exclusively to Alimentiv’s sponsoring clients and will provide advanced data insight alongside Alimentiv’s core reading services.
Certai was developed using a large global dataset of anonymized IBD colonoscopy videos, with data labeling and clinical oversight from the world’s leading experts in IBD assessment and scoring within clinical trials. “Using Certai is like having the world’s leading IBD experts at your side,” said Dr. Michael Byrne, CEO of Satisfai Health. Dr. Remo Pannacione, one of the world’s leading experts in the development of therapies for IBD, further commented that “standardization of the disease score using AI gives us a whole new level of knowledge that can make a real difference in the “how we control and analyze data, ultimately driving better results across the board.”
Certai will be available on Alimentiv’s NotÅ multimodal imaging platform, offering a single end-to-end solution that supports image review and centralized scoring. “The technical integration of Satisfai’s products into Alimentiv’s software provides a foundation for future advanced capabilities in digital biomarker identification, precision medicine and complementary diagnostics. We are excited to bring these advances in digital analytics to our portfolio,” said Jeff Smith, CEO of Alimentiv. By securing these exciting new technologies for use by sponsoring customers, Alimentiv will continue to lead the industry with more detailed and accurate analyses, highly competitive testing costs and faster turnaround times. Certai is not a medical device and is not used by healthcare professionals for clinical decision making or the provision of patient care.
About Satisfai Health:Satisfai Health is a leading medical software company specializing in the application of Artificial Intelligence technology to the evaluation of gastrointestinal diseases. Satisfai’s medical image analysis, clinical decision support, and precision medicine tools are used to improve disease assessment and measurement in clinical settings, as well as for the evaluation of patient data in clinical trials. Satisfai’s main capabilities focus on the endoscopic evaluation of diseases of the upper gastrointestinal tract (Barrett’s esophagus) and the lower gastrointestinal tract (colorectal cancer and inflammatory bowel disease), as well as novel applications of artificial intelligence to intestinal ultrasound. Satisfai Health has employed advanced digital technology to develop detailed and discrete scoring models for IBD within the scope and parameters of globally recognized scoring methodologies. For more information, visit: www.satisfai.health.
About Alimentiv:Alimentiv is a global contract research organization (CRO) focused on gastroenterology that provides clinical trials, central image management, precision medicine and real-world testing services to the pharmaceutical and biotechnology industries. Headquartered in London, Ontario, Alimentiv employs more than 500 people across operations in Canada, the United States, Europe, Asia-Pacific and Latin America. The organization’s unique model combines the efforts of internationally recognized academic researchers and operational experts to deliver integrated solutions to clients. Over the past 20 years, Alimentiv has become a recognized expert in clinical trial design, core image management solutions, outcome measures development, and precision medicine for GI drug development. Today, Alimentiv serves more than 50 countries around the world, collaborates with leading universities and academic institutions around the world, and works with many leading pharmaceutical and biotechnology organizations to offer new and better treatment options to patients. Alimentiv is committed to investing in medical research and development, focusing on identifying barriers to drug development and seeking solutions that advance GI research. The research results are translated into an effective clinical trial methodology for clients that conforms to new regulatory standards. In collaboration with leading experts, Alimentiv has pioneered the development, validation and standardization of outcome measures and technology, shaping the evolving landscape of clinical trials for multiple indications and providing significant long-term consequences for patients, their treatment and society. For more information, visit: www.alimentiv. com
Alimentiv, Inc., Contact: Fern Livingstone, Tel: 519.639.3205, Email: fern.livingstone@alimentiv.com; Satisfai Health, Contact: Russell Cabeliza, Tel: 204.297.6803, russell@satisfai.health
Logo – https://mma.prnewswire.com/media/2240437/Alimentiv_Inc__Alimentiv_and_Satisfai_Health_Announce_Commercial.jpgLogo – https://mma.prnewswire.com/media/2240438/Alimentiv_Inc__Alimentiv_and_Satisfai_Health_Announce_Commercial.jpg
View original content: https://www.prnewswire.com/news-releases/alimentiv-y-satisfai-health-anuncian-la-disponibilidad-comercial-de-una-innovadora-herramienta-de-puntuacion-301949622.html
